About Intec Pharma (NASDAQ:NTEC)
Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs. The Company is focusing on the clinical development program for the Phase III clinical study of the Accordion Pill Carbidopa Levodopa (AP-CDLD), for the treatment of advanced stages Parkinson’s disease patients. Its pipeline also comprises The Accordion Pill-Zaleplon, a drug for sleep onset, which is in Phase II clinical program. Furthermore under research is Accordion Pill-Undisclosed Drug for the prevention and treatment of small bowel non-steroidal anti-inflammatory drug (NSAID) induced ulcers.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$1.98 per share
Price / Book2.70
Return on EquityN/A
Return on AssetsN/A
Intec Pharma (NASDAQ:NTEC) Frequently Asked Questions
What is Intec Pharma's stock symbol?
Intec Pharma trades on the NASDAQ under the ticker symbol "NTEC."
How were Intec Pharma's earnings last quarter?
Intec Pharma Ltd. (NASDAQ:NTEC) posted its quarterly earnings results on Thursday, November, 5th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by $0.09. View Intec Pharma's Earnings History.
When will Intec Pharma make its next earnings announcement?
Where is Intec Pharma's stock going? Where will Intec Pharma's stock price be in 2017?
4 brokers have issued 1-year price objectives for Intec Pharma's stock. Their predictions range from $8.00 to $15.00. On average, they anticipate Intec Pharma's stock price to reach $12.00 in the next twelve months. View Analyst Ratings for Intec Pharma.
What are Wall Street analysts saying about Intec Pharma stock?
Here are some recent quotes from research analysts about Intec Pharma stock:
- 1. According to Zacks Investment Research, "Intec Pharma Ltd. is a biopharmaceutical company. The company focused on developing drugs through proprietary Accordion Pill platform technology. Its product candidates in clinical trial stages consists of Accordion Pill Carbidopa/Levodopa developed for the indication of treatment of Parkinson's disease symptoms; Accordion Pill Zaleplon is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance. Intec Pharma Ltd. is based in JERUSALEM, Israel. " (11/22/2017)
- 2. Maxim Group analysts commented, "Intec reported 3Q17 with a net loss of $7.7M and ended the period with $63.0M in cash, including proceeds from a $57.5M equity financing. At the current burn rate, we estimate the company has runway into late 2019." (11/17/2017)
Who are some of Intec Pharma's key competitors?
Some companies that are related to Intec Pharma include Oxford BioMedica (OXB), Pieris Pharmaceuticals (PIRS), Arrowhead Pharmaceuticals (ARWR), Endocyte (ECYT), Faron Pharmaceuticals Oy (FARN), Selecta Biosciences (SELB), Zymeworks (ZYME), Minerva Neurosciences (NERV), Foamix Pharmaceuticals (FOMX), Kindred Biosciences (KIN), ImmuPharma (IMM), Tocagen (TOCA), Athersys (ATHX), Vital Therapies (VTL), Chimerix (CMRX), Threshold Pharmaceuticals (MTEM), Forward Pharma A/S (FWP) and Vascular Biogenics (VBLT).
Who are Intec Pharma's key executives?
Intec Pharma's management team includes the folowing people:
- John W. Kozarich, Chairman of the Board (Age 67)
- Jeffrey A. Meckler, Chief Executive Officer, Vice Chairman of the Board (Age 50)
- Nir Sassi, Chief Financial Officer (Age 41)
- Nadav Navon, Chief Operating Officer (Age 48)
- Walt Addison Linscott, Chief Administrative Officer (Age 57)
- Liat Flaishon, Vice President-Clinical and Business Development (Age 48)
When did Intec Pharma IPO?
(NTEC) raised $30 million in an initial public offering (IPO) on Tuesday, August 4th 2015. The company issued 5,000,000 shares at a price of $6.00 per share. Maxim Group and Roth Capital Partners served as the underwriters for the IPO.
Who owns Intec Pharma stock?
Intec Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Sectoral Asset Management Inc (1.46%), Pura Vida Investments LLC (0.41%) and Caxton Corp (0.31%). View Institutional Ownership Trends for Intec Pharma.
Who bought Intec Pharma stock? Who is buying Intec Pharma stock?
How do I buy Intec Pharma stock?
Shares of Intec Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intec Pharma's stock price today?
One share of Intec Pharma stock can currently be purchased for approximately $5.35.
How big of a company is Intec Pharma?
Intec Pharma has a market capitalization of $139.49 million. Intec Pharma employs 56 workers across the globe.
How can I contact Intec Pharma?
Intec Pharma's mailing address is 12 Hartom Street RMPE building P.O.Box 45219, Jerusalem L3, 91450. The biotechnology company can be reached via phone at 972-2586-4657 or via email at [email protected]
MarketBeat Community Rating for Intec Pharma (NTEC)MarketBeat's community ratings are surveys of what our community members think about Intec Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Intec Pharma (NASDAQ:NTEC) Earnings History and Estimates Chart
Intec Pharma (NASDAQ NTEC) Earnings History by Quarter
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|4/6/2018|| || || || || || || || |
Intec Pharma (NASDAQ:NTEC) Earnings Estimates
2017 EPS Consensus Estimate: ($1.20)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Intec Pharma (NASDAQ:NTEC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Intec Pharma (NASDAQ NTEC)
No insider trades for this company have been tracked by MarketBeat.com
Intec Pharma (NASDAQ NTEC) News Headlines
Intec Pharma (NASDAQ:NTEC) SEC Filings
Intec Pharma (NASDAQ:NTEC) Income Statement, Balance Sheet and Cash Flow Statement
Intec Pharma (NASDAQ NTEC) Stock Chart for Monday, December, 11, 2017